512 related articles for article (PubMed ID: 35956911)
1. Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders.
Yousaf M; Chang D; Liu Y; Liu T; Zhou X
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956911
[TBL] [Abstract][Full Text] [Related]
2. Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review.
Singh K; Bhushan B; Chanchal DK; Sharma SK; Rani K; Yadav MK; Porwal P; Kumar S; Sharma A; Virmani T; Kumar G; Noman AA
Behav Neurol; 2023; 2023():8825358. PubMed ID: 37868743
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Polymer-Based Cannabidiol Formulation: Tackling Neuroinflammation Associated with Ischemic Events in the Brain.
Chevalier MT; Al-Waeel M; Alsharabasy AM; Rebelo AL; Martin-Saldaña S; Pandit A
Mol Pharm; 2024 Apr; 21(4):1609-1624. PubMed ID: 38412451
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
Tambe SM; Mali S; Amin PD; Oliveira M
J Integr Med; 2023 May; 21(3):236-244. PubMed ID: 36973157
[TBL] [Abstract][Full Text] [Related]
5. Studies of involvement of G-protein coupled receptor-3 in cannabidiol effects on inflammatory responses of mouse primary astrocytes and microglia.
Wu J; Chen N; Liu Y; Godlewski G; Kaplan HJ; Shrader SH; Song ZH; Shao H
PLoS One; 2021; 16(5):e0251677. PubMed ID: 33984046
[TBL] [Abstract][Full Text] [Related]
6. Molecular Targets of Cannabidiol in Neurological Disorders.
Ibeas Bih C; Chen T; Nunn AV; Bazelot M; Dallas M; Whalley BJ
Neurotherapeutics; 2015 Oct; 12(4):699-730. PubMed ID: 26264914
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.
Ożarowski M; Karpiński TM; Zielińska A; Souto EB; Wielgus K
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919010
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol: State of the art and new challenges for therapeutic applications.
Pisanti S; Malfitano AM; Ciaglia E; Lamberti A; Ranieri R; Cuomo G; Abate M; Faggiana G; Proto MC; Fiore D; Laezza C; Bifulco M
Pharmacol Ther; 2017 Jul; 175():133-150. PubMed ID: 28232276
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/NF-κB-dependent signaling and glucose consumption.
Dos-Santos-Pereira M; Guimarães FS; Del-Bel E; Raisman-Vozari R; Michel PP
Glia; 2020 Mar; 68(3):561-573. PubMed ID: 31647138
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.
Aziz AI; Nguyen LC; Oumeslakht L; Bensussan A; Ben Mkaddem S
Cannabis Cannabinoid Res; 2023 Apr; 8(2):254-269. PubMed ID: 36413346
[No Abstract] [Full Text] [Related]
11. Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer's Disease Neurodegeneration.
Chen L; Sun Y; Li J; Liu S; Ding H; Wang G; Li X
Cells; 2023 Nov; 12(23):. PubMed ID: 38067101
[TBL] [Abstract][Full Text] [Related]
12. Non-psychotropic Cannabis sativa L. phytocomplex modulates microglial inflammatory response through CB2 receptors-, endocannabinoids-, and NF-κB-mediated signaling.
Borgonetti V; Benatti C; Governa P; Isoldi G; Pellati F; Alboni S; Tascedda F; Montopoli M; Galeotti N; Manetti F; Miraldi E; Biagi M; Rigillo G
Phytother Res; 2022 May; 36(5):2246-2263. PubMed ID: 35393641
[TBL] [Abstract][Full Text] [Related]
13. Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease.
Hickey JP; Collins AE; Nelson ML; Chen H; Kalisch BE
Curr Issues Mol Biol; 2024 May; 46(5):4379-4402. PubMed ID: 38785534
[TBL] [Abstract][Full Text] [Related]
14. A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders.
Omotayo OP; Lemmer Y; Mason S
J Cannabis Res; 2024 Mar; 6(1):14. PubMed ID: 38494488
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders.
de Fátima Dos Santos Sampaio M; de Paiva YB; Sampaio TB; Pereira MG; Coimbra NC
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):574-601. PubMed ID: 38477419
[TBL] [Abstract][Full Text] [Related]
16. CBD Suppression of EAE Is Correlated with Early Inhibition of Splenic IFN-γ + CD8+ T Cells and Modest Inhibition of Neuroinflammation.
Nichols JM; Kummari E; Sherman J; Yang EJ; Dhital S; Gilfeather C; Yray G; Morgan T; Kaplan BLF
J Neuroimmune Pharmacol; 2021 Jun; 16(2):346-362. PubMed ID: 32440886
[TBL] [Abstract][Full Text] [Related]
17. Neurological Aspects of Medical Use of Cannabidiol.
Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol goes nuclear: The role of PPARγ.
Khosropoor S; Alavi MS; Etemad L; Roohbakhsh A
Phytomedicine; 2023 Jun; 114():154771. PubMed ID: 36965374
[TBL] [Abstract][Full Text] [Related]
19. Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.
Zavala-Tecuapetla C; Luna-Munguia H; López-Meraz ML; Cuellar-Herrera M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555823
[TBL] [Abstract][Full Text] [Related]
20. Emerging potential of cannabidiol in reversing proteinopathies.
Dash R; Ali MC; Jahan I; Munni YA; Mitra S; Hannan MA; Timalsina B; Oktaviani DF; Choi HJ; Moon IS
Ageing Res Rev; 2021 Jan; 65():101209. PubMed ID: 33181336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
